Case Reports
doi: 10.1038/sj.eye.6702352.
Epub 2006 Apr 7.
Adalimumab for sight-threatening uveitis in Behçet's disease
Affiliations
- PMID: 16601736
- DOI: 10.1038/sj.eye.6702352
Item in Clipboard
Case Reports
Adalimumab for sight-threatening uveitis in Behçet's disease
Eye (Lond).
2007 Jun.
Abstract
Aims: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods: Case note review. Main outcome measure was recurrence of uveitis.
Results: All patients remained free of recurrence with stable visual acuities.
Conclusions: Adalimumab appears to maintain disease remission in Behçet's disease.
Similar articles
-
Clinical experience with adalimumab in the treatment of ocular Behçet disease.Ocul Immunol Inflamm. 2010 Jun;18(3):226-32. doi: 10.3109/09273948.2010.483314. Ocul Immunol Inflamm. 2010. PMID: 20482404
-
Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S93. Epub 2011 Sep 27. Clin Exp Rheumatol. 2011. PMID: 21813069 No abstract available.
-
Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S58-62. Epub 2014 Jul 8. Clin Exp Rheumatol. 2014. PMID: 25005224
-
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17. Ophthalmology. 2014. PMID: 24359625
-
The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Semin Ophthalmol. 2011 Jul-Sep;26(4-5):295-303. doi: 10.3109/08820538.2011.588665. Semin Ophthalmol. 2011. PMID: 21958178 Review.
Cited by
-
Pharmacotherapy of scleritis: current paradigms and future directions.Expert Opin Pharmacother. 2013 Mar;14(4):411-24. doi: 10.1517/14656566.2013.772982. Epub 2013 Feb 21. Expert Opin Pharmacother. 2013. PMID: 23425055 Free PMC article. Review.
-
Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina.Mol Vis. 2013 Apr 17;19:894-903. Print 2013. Mol Vis. 2013. PMID: 23687426 Free PMC article.
-
Biologic agents in the management of inflammatory eye diseases.Curr Allergy Asthma Rep. 2008 Jul;8(4):339-47. doi: 10.1007/s11882-008-0054-2. Curr Allergy Asthma Rep. 2008. PMID: 18606088 Review.
-
Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Mediators Inflamm. 2013;2013:286857. doi: 10.1155/2013/286857. Epub 2013 Aug 1. Mediators Inflamm. 2013. PMID: 23983404 Free PMC article. Review.
-
Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.Int Ophthalmol. 2011 Apr;31(2):165-73. doi: 10.1007/s10792-011-9430-3. Epub 2011 Feb 2. Int Ophthalmol. 2011. PMID: 21287227 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
